Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 32 clinical trials
Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-

Alteplase for Acute Ischemic Stroke Within 4.5 Hours

  • 0 views
  • 05 Aug, 2021
  • 61 locations
Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients With Large Vessel Occlusion

allocation process to either standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg) or tenecteplase before undergoing intra-arterial clot retrieval. The trial is

ct scan
plasminogen
alteplase
stroke
probe
  • 0 views
  • 01 Jul, 2021
  • 7 locations
Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke (POST-ETERNAL)

treatment or intravenous alteplase 0.9mg/kg) or tenecteplase 0.25mg/kg before undergoing mechanical thrombectomy as required at treating clinician's discretion. The trial is Multi-arm, Multi-stage

  • 0 views
  • 19 Jun, 2022
  • 3 locations
REMOTE Ischemic Perconditioning Among Acute Ischemic Stroke Patients ( REMOTE-CAT) (REMOTE-CAT)

Stroke is one of the leading causes of death worldwide and the main cause of incapacity. Currently, the only therapies for acute ischemic stroke (AIS) patients are the administration of recombinant tissue plasminogen activator (rt-PA) and/or endovascular treatment. Unfortunately, many patients cannot benefit from these therapies due to contraindications or …

cerebral infarction
arterial occlusion
plasminogen
alteplase
stroke
  • 37 views
  • 23 Apr, 2022
  • 1 location
Adaptive Efficacy and Safety Study of Glenzocimab Used as an add-on Therapy on Top of Standard of Care un the 4.5 Hours Following an Acute Ischemic Stroke

A randomized, double blind, multicenter, multinational, placebo controlled, parallel group, single dose, adaptive phase II/III study (respectively Part 1 and 2). The study evaluates the efficacy and safety of a fixed dose of glenzocimab (1000 mg IV over 6 hrs including initial bolus of 15 minutes) on top of the …

  • 3 views
  • 13 Oct, 2021
  • 1 location
  • 0 views
  • 11 Mar, 2022
  • 14 locations
Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic Stroke

in combination with alteplase in patients with Acute Ischemic Stroke.

  • 0 views
  • 15 Jun, 2022
  • 1 location
Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke (DUMAS)

Randomized controlled phase II trial to test the safety and preliminary efficacy of a dual thrombolytic treatment consisting of a small intravenous (IV) bolus of alteplase followed by IV

thrombolytic therapy
plasminogen
thrombolytic agent
alteplase
stroke
  • 3 views
  • 26 Feb, 2022
  • 1 location
  • 0 views
  • 25 Mar, 2022
  • 1 location
A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion (THEIA)

The aim of the THEIA study is to determine if Alteplase administrated within 4.5 hours improve visual deficit due to acute CRAO with a good safety profile.

  • 30 views
  • 11 May, 2022
  • 14 locations